Michael D Ezekowitz

Summary

Affiliation: Lankenau Institute for Medical Research
Country: USA

Publications

  1. ncbi request reprint Stroke prevention in atrial fibrillation: anticoagulants and antithrombotics
    Michael D Ezekowitz
    Drexel University College of Medicine, 245 North 15th Street MS 470, Room 6608 NCB, Philadelphia, PA 19102, USA
    Am Heart Hosp J 2:31-5. 2004
  2. doi request reprint A randomized trial of budiodarone in paroxysmal atrial fibrillation
    Michael D Ezekowitz
    Lankenau Medical Center, Medical Science Building, Wynnewood, PA 19096, USA
    J Interv Card Electrophysiol 34:1-9. 2012
  3. ncbi request reprint Dabigatran with or without concomitant aspirin compared with warfarin alone in patients with nonvalvular atrial fibrillation (PETRO Study)
    Michael D Ezekowitz
    Lankenau Institute for Medical Research and The Heart Center, Wynnewood, PA, USA
    Am J Cardiol 100:1419-26. 2007
  4. doi request reprint Rationale and design of RE-LY: randomized evaluation of long-term anticoagulant therapy, warfarin, compared with dabigatran
    Michael D Ezekowitz
    Lankenau Institute for Medical Research and The Heart Center, Wynnewood, PA, USA
    Am Heart J 157:805-10, 810.e1-2. 2009
  5. doi request reprint The evolving field of stroke prevention in patients with atrial fibrillation
    Michael D Ezekowitz
    Lankenau Institute for Medical Research, 100 Lancaster Avenue, Wynnewood, PA 19096, USA
    Stroke 41:S17-20. 2010
  6. doi request reprint Dabigatran and warfarin in vitamin K antagonist-naive and -experienced cohorts with atrial fibrillation
    Michael D Ezekowitz
    Lankenau Institute for Medical Research, 100 Lancaster Ave, Suite G36, Wynnewood, PA 19096, USA
    Circulation 122:2246-53. 2010
  7. doi request reprint Dabigatran in atrial fibrillation: pharmacology and clinical trials
    Michael D Ezekowitz
    Lankenau Institute for Medical Research, 100 Lancaster Avenue, Suite G36, Wynnewood, PA, 19096, USA
    J Interv Card Electrophysiol 32:173-80. 2011
  8. doi request reprint Dabigatran versus warfarin in patients with atrial fibrillation: an analysis of patients undergoing cardioversion
    Rangadham Nagarakanti
    Louisiana State University School of Medicine, New Orleans, LA, USA
    Circulation 123:131-6. 2011
  9. doi request reprint Combination antiplatelet therapy for secondary stroke prevention: enhanced efficacy or double trouble?
    M Haris U Usman
    Lankenau Institute for Medical Research, Wynnewood, Pennsylvania, USA
    Am J Cardiol 103:1107-12. 2009
  10. doi request reprint Secondary prevention in concurrent coronary artery, cerebrovascular, and chronic kidney disease: focus on pharmacological therapy
    Lawrence A Notaro
    Lankenau Institute for Medical Research, Wynnewood, PA 19096, USA
    Cardiovasc Ther 27:199-215. 2009

Collaborators

Detail Information

Publications30

  1. ncbi request reprint Stroke prevention in atrial fibrillation: anticoagulants and antithrombotics
    Michael D Ezekowitz
    Drexel University College of Medicine, 245 North 15th Street MS 470, Room 6608 NCB, Philadelphia, PA 19102, USA
    Am Heart Hosp J 2:31-5. 2004
    ..It is highly likely that alternatives to warfarin for stroke prevention will be available in the future and will likely result in a higher utilization rate of anticoagulants in patients with atrial fibrillation...
  2. doi request reprint A randomized trial of budiodarone in paroxysmal atrial fibrillation
    Michael D Ezekowitz
    Lankenau Medical Center, Medical Science Building, Wynnewood, PA 19096, USA
    J Interv Card Electrophysiol 34:1-9. 2012
    ..The aim of this study was to investigate the preliminary safety and efficacy of three doses of budiodarone in patients with paroxysmal atrial fibrillation...
  3. ncbi request reprint Dabigatran with or without concomitant aspirin compared with warfarin alone in patients with nonvalvular atrial fibrillation (PETRO Study)
    Michael D Ezekowitz
    Lankenau Institute for Medical Research and The Heart Center, Wynnewood, PA, USA
    Am J Cardiol 100:1419-26. 2007
    ..The 2 highest doses of dabigatran suppress D-dimer concentrations. Serious liver toxicity was not seen. The significance of the increase of DTB2 concentrations in dabigatran-treated patients needs resolution...
  4. doi request reprint Rationale and design of RE-LY: randomized evaluation of long-term anticoagulant therapy, warfarin, compared with dabigatran
    Michael D Ezekowitz
    Lankenau Institute for Medical Research and The Heart Center, Wynnewood, PA, USA
    Am Heart J 157:805-10, 810.e1-2. 2009
    ..The worldwide site distribution and broad range of stroke risk further increase the general applicability of the trial. Results are expected in 2009...
  5. doi request reprint The evolving field of stroke prevention in patients with atrial fibrillation
    Michael D Ezekowitz
    Lankenau Institute for Medical Research, 100 Lancaster Avenue, Wynnewood, PA 19096, USA
    Stroke 41:S17-20. 2010
    ..Dabigatran is the first agent to show superiority over warfarin for stroke prevention in atrial fibrillation, raising the standard for newer agents...
  6. doi request reprint Dabigatran and warfarin in vitamin K antagonist-naive and -experienced cohorts with atrial fibrillation
    Michael D Ezekowitz
    Lankenau Institute for Medical Research, 100 Lancaster Ave, Suite G36, Wynnewood, PA 19096, USA
    Circulation 122:2246-53. 2010
    ..The comparison of anticoagulants dabigatran and warfarin might be most equitable in vitamin K antagonist (VKA)-naive patients...
  7. doi request reprint Dabigatran in atrial fibrillation: pharmacology and clinical trials
    Michael D Ezekowitz
    Lankenau Institute for Medical Research, 100 Lancaster Avenue, Suite G36, Wynnewood, PA, 19096, USA
    J Interv Card Electrophysiol 32:173-80. 2011
    ..Dabigatran, therefore, is the first novel anticoagulant to offer an alternative to warfarin...
  8. doi request reprint Dabigatran versus warfarin in patients with atrial fibrillation: an analysis of patients undergoing cardioversion
    Rangadham Nagarakanti
    Louisiana State University School of Medicine, New Orleans, LA, USA
    Circulation 123:131-6. 2011
    ..The Randomized Evaluation of Long-Term Anticoagulation Therapy (RE-LY) trial compared dabigatran 110 mg BID (D110) and 150 mg BID (D150) with warfarin for stroke prevention in 18 113 patients with nonvalvular atrial fibrillation...
  9. doi request reprint Combination antiplatelet therapy for secondary stroke prevention: enhanced efficacy or double trouble?
    M Haris U Usman
    Lankenau Institute for Medical Research, Wynnewood, Pennsylvania, USA
    Am J Cardiol 103:1107-12. 2009
    ..Aspirin plus ER-DP has a greater bleeding rate than clopidogrel but a lower rate than aspirin (< or =325 mg/day) alone...
  10. doi request reprint Secondary prevention in concurrent coronary artery, cerebrovascular, and chronic kidney disease: focus on pharmacological therapy
    Lawrence A Notaro
    Lankenau Institute for Medical Research, Wynnewood, PA 19096, USA
    Cardiovasc Ther 27:199-215. 2009
    ..There are no data supporting the use of aspirin plus clopidogrel in patients with CKD who develop ACS. Aspirin plus clopidogrel is contraindicated for stroke prevention...
  11. ncbi request reprint Images in cardiovascular medicine. The case of a disappearing left atrial appendage thrombus: direct visualization of left atrial thrombus migration, captured by echocardiography, in a patient with atrial fibrillation, resulting in a stroke
    Amit Parekh
    Lankenau Institute for Medical Research, 100 Lancaster Ave, Wynnewood, PA 19096 3425, USA
    Circulation 114:e513-4. 2006
  12. ncbi request reprint Department of Veterans Affairs Cooperative Studies Program Clinical Trial comparing combined warfarin and aspirin with aspirin alone in survivors of acute myocardial infarction: primary results of the CHAMP study
    Louis D Fiore
    Department of Veterans Affairs Cooperative Studies Program Coordinating Center, West Haven, Connecticut, USA
    Circulation 105:557-63. 2002
    ..28 versus 0.72 events per 100 person years of follow-up, respectively; P<0.001). There were 14 individuals with intracranial bleeds in both the aspirin and combination therapy groups...
  13. ncbi request reprint Warfarin therapy and systolic hypertension in men with atrial fibrillation
    Subramanian Krishnan
    Department of Medicine, University of Connecticut School of Medicine, Farmington, Connecticut 06516, USA
    Am J Hypertens 18:1592-9. 2005
    ..We performed post hoc analyses of the Stroke Prevention in Non-Rheumatic Atrial Fibrillation (SPINAF) trial, aiming to analyze the effects of warfarin on SBP and PP...
  14. ncbi request reprint Combination antithrombotic therapy with antiplatelet agents and anticoagulants for patients with atherosclerotic heart disease
    Heidar Arjomand
    Division of Cardiology, Department of Medicine, MCP Hahnemann University Hospitals, Drexel University College of Medicine, Philadelphia, Pennsylvania, USA
    J Invasive Cardiol 16:271-8. 2004
    ..0-2.5) in high-risk patients with atherosclerotic heart disease. Combination therapy increases the risk of minor and major bleeding, but not intracranial bleeding...
  15. ncbi request reprint Anticoagulation in the elderly
    Abhay J Dhond
    Department of Medicine, Drexel University College of Medicine, Philadelphia, PA 19102, USA
    Am J Geriatr Cardiol 12:243-50. 2003
    ....
  16. ncbi request reprint Anticoagulation interruptus: not without risk
    Michael D Ezekowitz
    Circulation 110:1518-9. 2004
  17. ncbi request reprint The increasing need for anticoagulant therapy to prevent stroke in patients with atrial fibrillation
    Michael D Ezekowitz
    Department of Medicine, Drexel University College of Medicine, Philadelphia, PA 19102, USA
    Mayo Clin Proc 79:904-13. 2004
    ....
  18. ncbi request reprint Comparison of sotalol versus amiodarone in maintaining stability of sinus rhythm in patients with atrial fibrillation (Sotalol-Amiodarone Fibrillation Efficacy Trial [Safe-T])
    Steven N Singh
    Division of Cardiology, Veterans Affairs Medical Center, Washington, DC 20422, USA
    Am J Cardiol 92:468-72. 2003
    ..SAFE-T had randomized 665 patients when enrollment terminated on October 31, 2001. Follow-up of patients continued until October 31, 2002, for a maximum period of 54 months and a minimum period of 12 months for all patients...
  19. ncbi request reprint Anticoagulation in management of atrial fibrillation
    Michael D Ezekowitz
    Department of Medicine, Drexel University College of Medicine, 245 N 15th Street, Mail Stop 487, Philadelphia, PA 19102, USA
    Curr Opin Cardiol 18:26-31. 2003
    ....
  20. ncbi request reprint Cholesterol-induced thrombogenicity of the vessel wall: inhibitory effect of fluvastatin
    Marina Camera
    Department of Pharmacological Sciences, University of Milan, Italy
    Thromb Haemost 87:748-55. 2002
    ..Fluvastatin treatment reduces the prothrombotic tendency by inhibiting TF synthesis...
  21. ncbi request reprint Anticoagulation management of valve replacement patients
    Michael D Ezekowitz
    Department of Medicine, MCP Hahnemann University, Philadelphia, Pennsylvania, USA
    J Heart Valve Dis 11:S56-60. 2002
    ..In patients who are hemodynamically stable, thrombolytic therapy is recommended initially...
  22. ncbi request reprint The impact of patient self-testing of prothrombin time for managing anticoagulation: rationale and design of VA Cooperative Study #481--the Home INR Study (THINRS)
    David B Matchar
    Health Services Research Field Program, Duke University Medical Center, Center for Clinical Health Policy Research, VA Medical Center, 2200 W Main St, Suite 220, Durham, NC, 27705, USA
    J Thromb Thrombolysis 19:163-72. 2005
    ..PST in THINRS involves use of an INR monitoring device that is FDA approved for home use...
  23. ncbi request reprint Epidemiology and management of new-onset atrial fibrillation
    Khalid Abusaada
    Department of Medicine, Drexel University School of Medicine, Philadelphia, Pennsylvania, USA
    Am J Manag Care 10:S50-7. 2004
    ..This article will describe in detail the acute management of AF as well as its epidemiology...
  24. doi request reprint ACC/AHA/Physician Consortium 2008 Clinical Performance Measures for Adults with Nonvalvular Atrial Fibrillation or Atrial Flutter: a report of the American College of Cardiology/American Heart Association Task Force on Performance Measures and the Physici
    N A Mark Estes
    J Am Coll Cardiol 51:865-84. 2008
  25. doi request reprint ACC/AHA/Physician Consortium 2008 clinical performance measures for adults with nonvalvular atrial fibrillation or atrial flutter: a report of the American College of Cardiology/American Heart Association Task Force on Performance Measures and the Physici
    N A Mark Estes
    Circulation 117:1101-20. 2008
  26. doi request reprint Letter regarding article by Connolly et al, "Challenges of establishing new antithrombotic therapies in atrial fibrillation"
    Michael D Ezekowitz
    Circulation 117:e149; author reply e150. 2008
  27. ncbi request reprint Maintaining sinus rhythm--making treatment better than the disease
    Michael D Ezekowitz
    N Engl J Med 357:1039-41. 2007
  28. ncbi request reprint Amiodarone versus sotalol for atrial fibrillation
    Bramah N Singh
    Department of Veterans Affairs Medical Center, West Los Angeles, Calif 90073, USA
    N Engl J Med 352:1861-72. 2005
    ..The optimal pharmacologic means to restore and maintain sinus rhythm in patients with atrial fibrillation remains controversial...
  29. ncbi request reprint Review of antiplatelet therapy in secondary prevention of cerebrovascular events: a need for direct comparisons between antiplatelet agents
    Dara G Jamieson
    University of Pennsylvania Penn Neurological Institute, USA
    J Cardiovasc Pharmacol Ther 10:153-61. 2005
    ....
  30. ncbi request reprint Quality of life and exercise performance in patients in sinus rhythm versus persistent atrial fibrillation: a Veterans Affairs Cooperative Studies Program Substudy
    Steven N Singh
    Department of Veterans Affairs Medical Center, Washington, DC 20422, USA
    J Am Coll Cardiol 48:721-30. 2006
    ..The purpose of this study was to determine quality of life (QOL) and exercise performance (EP) in patients with persistent atrial fibrillation (AF) converted to sinus rhythm (SR) compared with those remaining in or reverting to AF...